Log In
BCIQ
Print this Print this
 

AF-130

  Manage Alerts
Collapse Summary General Information
Company Roche
DescriptionSecond generation purinergic receptor P2X ligand-gated ion channel 3 (P2X3) receptor antagonist
Molecular Target Purinergic receptor P2X ligand-gated ion channel 3 (P2X3)
Mechanism of ActionP2RX3 antagonist
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1,250.0M

$500.0M

$750.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/27/2016

$1,250.0M

$500.0M

$750.0M

Get a free BioCentury trial today